Successful Oral Desensitization with Dasatinib in Delayed Cutaneous Hypersensitivity Reactions
Dasatinib (Bristol-Myers Squibb) is a short-acting inhibitor of multiple tyrosine kinases which is used orally in treatment of chronic myeloid leukemia, Philadelphia-chromosome positive acute Lymphoblastic leukemia (ALL), solid tumors and systemic mastocytosis . Despite acceptable safety profile of dasatinib, cutaneous adverse reactions including xerosis, keratosis pilaris, pruritus, maculopapular/exfoliative rashes, edema, alopecia may limit its use in crucial conditions . In case of drug-related cutaneous rashes, the primary approach is withdrawal of the culprit agent and introduction of supportive treatment.
Conclusions: COS showed anti-allergy properties by regulating the levels of Th1 and Th2 cytokines.Int Arch Allergy Immunol
Several human polyomaviruses, including Merkel cell polyomavirus, have been isolated on the skin. Which are associated with cutaneous disease, and what do we know about their molecular mechanisms?The British Journal of Dermatology
AbstractPurpose of ReviewTo highlight recent results in targeting mRNA translation and discuss the results and prospects of translation inhibitors in cancer therapy.Recent FindingsUntil recently, inhibitors of mRNA translation have been thought to likely lack a therapeutic window. In 2012, the Food and Drug Administration (FDA) approved omacetaxine mepesuccinate (homoharringtonine) for the treatment of adults with chronic myelogenous leukemia (CML) who are resistant to at least two tyrosine kinase inhibitors. Since then, a few drugs, notably tomivosertib (eFT-508), selinexor (KPT-330), and ribavirin, have entered clinical ...
Injuries from cosmetics, shampoo and other personal care products send one young child to an emergency department in the United States every two hours, according to a new study.Reuters Health Information
Authors: Bewersdorf JP, Stahl M, Zeidan AM Abstract Key paper evaluation: Craddock C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019; 37: 580-8. Allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only potentially curative treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, most patients relapse after allo-HSCT and treatment options are limited. Craddock et al. reported recently in the Journal of Clinical Oncology results from a ...
CONCLUSIONS: The current study may serve as a preliminary data to suggest that the addition of LEN may offer incremental benefit to patients with high-risk MDS, AML and CMML. However, randomized-controlled studies that directly compare the efficacy and adverse events of AZA-plus-LEN regimen versus AZA monotherapy are still needed. PMID: 31221030 [PubMed - in process]
Abstract OBJECTIVES: To describe the impact of central nervous system-directed treatment on attention and its relation to academic outcomes in childhood acute lymphoblastic leukemia (ALL) survivors. SAMPLE & SETTING: 51 children diagnosed with ALL at two pediatric oncology treatment centers in the southwestern United States. METHODS & VARIABLES: A prospective, longitudinal design measured attention after a child was in remission, two years after the start of treatment, and at the end of treatment. Attention measures from the Conners' Continuous Performance Test were grouped into composite subdoma...
Publication date: Available online 22 June 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Danijela Bokanovic, Lisa Arzt-Gradwohl, Ines Schwarz, Christoph Schrautzer, Karin Laipold, Werner Aberer, Barbara Binder, Gunter J. Sturm
ConclusionsThe impact of exposure is dose-related and linked to the sensitization step which may subsequently lead to allergy development. For primary prevention of enzyme allergy, exposure control is mandatory and achievable despite increasing production volumes.
Publication date: Available online 22 June 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Erika J. Yoo, Nora L. Lee, Kelly P. Huang, Lara T. Kose, Deval Desai, Lauren A. Plante, Edward S. Schulman